Silicon Therapeutics (Silicon Tx), an integrated computational drug discovery company creating novel small molecule therapeutics for difficult to target proteins, has announced the appointment of Woody Sherman Ph.D., as chief scientific officer to lead the development and application of its INSITE platform as STX continues its trajectory toward being the first truly integrated computational drug discovery company with massive physics-based simulations tightly integrated within their drug discovery and design workflows.
“I am thrilled to be part of Silicon Therapeutics’ mission to develop better medicines more efficiently by applying the most advanced simulation methods to important drug targets. Silicon has been founded on the principle that the accurate computational methods coupled with new technologies, such as cloud and GPU computing, will revolutionize the design of new medicines,” said Dr. Sherman. “We are at the dawn of a new era where massive physics-based simulations can be performed fast enough to significantly impact the drug discovery process. We are building the first truly integrated computational drug discovery company where the computational platform will be tightly coupled with experimentation to increase the quality and speed of each design cycle, thereby streamlining the pre-clinical drug discovery process. I am committed to help Silicon become a leading biopharmaceutical company based on these principles.”
“Woody’s expertise and over 15 years’ experience as a leader in computational method development and drug design will provide Silicon with significant advantages as we continue to push forward as an industry leader at the intersection of massive computation and drug discovery,” said Lanny Sun, CEO of Silicon Therapeutics. “We are extremely pleased and honored to be able to work with Dr. Sherman and look forward to continued advancements in targeting difficult to drug proteins with him on-board.”
Dr. Sherman is a leader in molecular simulations and computer-aided drug design, with over 70 publications covering novel methods and applications. He completed his Ph.D. at MIT with Professor Bruce Tidor, where he examined the role of electrostatics in protein-ligand binding and implemented a novel method for optimizing ligand binding specificity across a panel of (desirable and undesirable) targets. He then joined Schrödinger, a leader in computational chemistry software development, where he was global head of the Applications Science team, helping biopharma companies apply computational chemistry tools to challenging problems. He was also part of the senior management team and was involved in modeling services, methods development and product management. Dr. Sherman has published on a broad range of topics, including free energy simulations, molecular dynamics, induced-fit docking, virtual screening, lead optimization, cheminformatics and protein design. He is on the Editorial Board of Chemical Biology & Drug Design and Journal of Chemical Information and Modeling.
Silicon Tx, an integrated computational drug discovery company, is focused on targeting the high hanging fruits within drug discovery that are currently considered to be challenging or out of reach using traditional approaches. Silicon Tx is developing the most accurate in silico methods to overcome bottlenecks in drug discovery and accelerate the process of finding new medicines to treat important diseases.